☆ 4.1 Article

Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients

PROTEOMICS CLINICAL APPLICATIONS (2010)

Journal

PROTEOMICS CLINICAL APPLICATIONS

Volume 4, Issue 12, Pages 940-952

Publisher

WILEY-V C H VERLAG GMBH

DOI: 10.1002/prca.200900171

Keywords

Ovarian cancer; Survival

Categories

Biochemical Research Methods Biochemistry & Molecular Biology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Purpose: To determine if the level of apolipoprotein A1, hepcidin, transferrin, inter-a trypsin IV internal fragment, transthyretin (TT), connective-tissue activating protein 3 (CTAP3), serum amyloid A1, beta-2 microglobulin (B2M) might have impact on overall and progression-free survival for ovarian cancer (OC) patients. Experimental design: Serum from 150 OC patients was tested using SELDI-TOF-MS. Results: A proteomic prognostic index (xb-pro) was constructed using the regression coefficients based on inter-alpha trypsin IV internal fragment, B2M and TT. A multivariable Cox survival analysis including the xb-pro index showed that xb-pro (p<0.0001, HR = 2.50, 95% CI: 1.65-3.79), residual tumor after primary surgery (p = 0.0005), age (p = 0.01) and chemotherapy (p = 0.0002) are of independent prognostic value for overall survival. International Federation of Gynecology and Obstetrics stage, performance status, histological type of tumor and serum CA125 were found of no independent value. A proteomic index (xb-pfs) based on B2M and CTAP3 was found to predict progression-free survival (xb-pfs: p = 0.008, HR = 1.77, 95% CI: 1.17-2.70 together with type of surgery, age and chemotherapy. Conclusions and clinical relevance: We found an index with three proteomic biomarkers (xb-pro) to be of independent prognostic value for overall survival and an index with two proteomic biomarkers (xb-pfs) with evidence of independent prognostic value for progression-free survival.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Editorial Material Oncology

Tissue residency of memory CD8+ T cells matters in shaping immunogenicity of ovarian cancer

Takemasa Tsuji, Junko Matsuzaki, Kunle Odunsi

Summary: In this study, Anadon et al. conducted a multi-omics analysis on ovarian tumor infiltrating tissue-resident memory T (TRM) cells at the single-cell level. The results provide evidence for a differentiation model from CD103(-) TCF1(+) re-circulating T-cell precursors driven by tumor antigen recognition. CD103(+) TRM cells play a dominant anti-tumor role in ovarian cancer.

CANCER CELL (2022)

Add to Collection

Article Oncology

Racial disparities in epithelial ovarian cancer survival: An examination of contributing factors in the Ovarian Cancer in Women of African Ancestry consortium

Holly R. Harris, Kristin A. Guertin, Tareq F. Camacho, Courtney E. Johnson, Anna H. Wu, Patricia G. Moorman, Evan Myers, Traci N. Bethea, Elisa Bandera, Charlotte E. Joslin, Heather M. Ochs-Balcom, Lauren C. Peres, Will T. Rosenow, Veronica W. Setiawan, Alicia Beeghly-Fadiel, Lauren F. Dempsey, Lynn Rosenberg, Joellen M. Schildkraut

Summary: Black women diagnosed with epithelial ovarian cancer have lower survival rates compared to white women. Factors such as education, lifestyle, diabetes, hormone therapy, and tumor characteristics contribute to this disparity.

INTERNATIONAL JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Conditional Relative Survival of Ovarian Cancer: A Korean National Cancer Registry Study

Dong Wook Shin, Jaeman Bae, Johyun Ha, Kyu-Won Jung

Summary: The study presents 5-year relative conditional survival probabilities for ovarian cancer patients from 1997-2016. The results showed that the conditional survival rates increased with each year survived, but even after 5 years, the excess mortality did not reach 'no excess mortality' level. Patients with poorer initial prognoses showed the largest improvements in conditional survival rates.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Prognostic immunologic signatures in epithelial ovarian cancer

Nicole E. James, Morgan Woodman, Jennifer R. Ribeiro

Summary: EOC patients have low response rates to immunotherapies, but evidence suggests ovarian tumors are immunogenic and immune-related genomic profiles can serve as prognostic markers. Specific research areas that need to be addressed include developing immune-based prognostic signatures and driving advancements in this field.

ONCOGENE (2022)

Add to Collection

Article Obstetrics & Gynecology

Health Disparities in Ovarian Cancer Report From the Ovarian Cancer Evidence Review Conference

Shirley Mei, David Chelmow, Kimberly Gecsi, Joel Barkley, Emily Barrows, Rebecca Brooks, Kathryn Huber-Keener, Myrlene Jeudy, Julia Sage O'Hara, William Burke

Summary: Health disparity, which refers to preventable differences in disease burden and health opportunities among socially disadvantaged populations, is prevalent in ovarian cancer outcomes. Factors such as race, ethnicity, insurance, socioeconomic status, and geographic location contribute to disparities in survival, treatment, and stage at diagnosis. Limited evidence suggests that adherence to treatment guidelines can help mitigate these disparities.

OBSTETRICS AND GYNECOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

IgA transcytosis and antigen recognition govern ovarian cancer immunity

Subir Biswas, Gunjan Mandal, Kyle K. Payne, Carmen M. Anadon, Chandler D. Gatenbee, Ricardo A. Chaurio, Tara Lee Costich, Carlos Moran, Carly M. Harro, Kristen E. Rigolizzo, Jessica A. Mine, Jimena Trillo-Tinoco, Naoko Sasamoto, Kathryn L. Terry, Douglas Marchion, Andrea Buras, Robert M. Wenham, Xiaoqing Yu, Mary K. Townsend, Shelley S. Tworoger, Paulo C. Rodriguez, Alexander R. Anderson, Jose R. Conejo-Garcia

Summary: Most ovarian cancers are infiltrated by activated T cells that have prognostic relevance, but they show low response rates to immune checkpoint inhibitors. On the contrary, memory B cell and plasma cell infiltrates associated with better outcomes may exert protective effects against tumor cells through B cell-derived IgA in ovarian cancer.

NATURE (2021)

Add to Collection

Article Nutrition & Dietetics

Pre-diagnosis Dairy Product Intake and Ovarian Cancer Mortality: Results From the Ovarian Cancer Follow-Up Study (OOPS)

Luo Jiang, Ting-Ting Gong, Song Gao, Xiu-Qin Li, Fang-Hua Liu, Zhao-Yan Wen, Yi-Fan Wei, Shi Yan, Rui Hou, Qi-Jun Wu

Summary: Pre-diagnosis dairy product consumption, including protein, fat, and calcium intake, was associated with higher mortality among ovarian cancer survivors. Specific components of dairy intake such as protein, fat, and calcium were linked to increased mortality among patients.

FRONTIERS IN NUTRITION (2021)

Add to Collection

Review Oncology

Surgery in Recurrent Ovarian Cancer: A Meta-Analysis

Maria Teresa Climent, Anna Serra, Maria Llueca, Antoni Llueca

Summary: Ovarian cancer has a high mortality rate due to advanced diagnosis and high recurrence rate. Systemic chemotherapy is the standard treatment for recurrent ovarian cancer, but secondary cytoreductive surgery may also be effective. This study analyzed multiple randomized controlled trials and found significant improvements in overall survival and disease-free survival for patients who underwent complete secondary cytoreductive surgery.

CANCERS (2023)

Add to Collection

Article Multidisciplinary Sciences

Connections between prolactin and ovarian cancer

Amira Alkharusi, Abdullah AlMuslahi, Najwa AlBalushi, Radiya AlAjmi, Sami AlRawahi, Asmaa AlFarqani, Gunnar Norstedt, Fahad Zadjali

Summary: This study investigates the effects of prolactin on ovarian cancer cells, analyzes the expression of PRL receptors in tissue, and links PRLR expression to ovarian cancer survival. The results suggest that PRLR may play a role in promoting tumor aggressiveness and influencing survival rates in ovarian cancer.

PLOS ONE (2021)

Add to Collection

Article Medicine, General & Internal

Prediagnosis Depression Rather Than Anxiety Symptoms Is Associated with Decreased Ovarian Cancer Survival: Findings from the Ovarian Cancer Follow-Up Study (OOPS)

Yi-Zi Li, Xue Qin, Fang-Hua Liu, Wen-Xiao Chen, Yi-Fan Wei, Na Wang, Shi Yan, Ye Kang, Yu-Hong Zhao, Song Gao, Ting-Ting Gong, Qi-Jun Wu

Summary: This study examined the relationship between prediagnosis depression, anxiety symptoms, and ovarian cancer survival. The results suggest that prediagnosis depression may increase the risk of ovarian cancer mortality, while there is no association between anxiety symptoms and ovarian cancer mortality. Interestingly, patients with moderate depression and anxiety symptoms have a higher risk of ovarian cancer mortality.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Oncology

Germline BRCA variants, lifestyle and ovarian cancer survival

Kate Gersekowski, Rachel Delahunty, Kathryn Alsopb, Ellen L. Goode, Julie M. Cunningham, Stacey J. Winham, Paul Pharoah, Honglin Song, Susan Jordan, Sian Fereday, Anna DeFazio, Michael Friedlander, Andreas Obermair, Penelope M. Webb

Summary: The adverse effect of smoking on survival may be stronger for women with a BRCA variant, while the associations between physical activity, BMI, and alcohol intake and survival are unclear.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Review Endocrinology & Metabolism

Mechanisms of Ovarian Cancer-Associated Cachexia

Chandler S. Callaway, Lila M. Mouchantat, Benjamin G. Bitler, Andrea Bonetto

Summary: Cancer-associated cachexia is a common occurrence in cancer patients, including those with ovarian cancer. Reduced skeletal muscle mass in ovarian cancer patients is associated with worse outcomes. Mouse models show characteristics of cachexia in ovarian cancer, but there is limited research on ovarian cancer-associated cachexia compared to other cancer types. Certain soluble factors may serve as therapeutic targets for mitigating cachexia in ovarian cancer. However, more research is needed to determine the translational relevance of these findings due to the relatively low number of studies.

ENDOCRINOLOGY (2023)

Add to Collection

Review Cell Biology

Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer

Seiji Mabuchi, Tomoyuki Sasano, Naoko Komura

Summary: Myeloid-derived suppressor cells (MDSCs) play a crucial role in ovarian cancer, with increased frequencies associated with poor prognosis. Depletion of MDSCs can significantly inhibit tumor growth and enhance the efficacy of existing anticancer therapies.

CELLS (2021)

Add to Collection

Article Oncology

Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study

Azam Majidi, Renhua Na, Susan J. Jordan, Anna De Fazio, Penelope M. Webb

Summary: Research on the potential survival benefits of statins in women with ovarian cancer found that the use of lipophilic statins may be associated with reduced mortality, especially among women with hyperlipidaemia. Further investigation in larger cohorts or randomized trials is needed to validate these findings.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Antihypertensive Drug Use and the Risk of Ovarian Cancer Death among Finnish Ovarian Cancer Patients-A Nationwide Cohort Study

Eerik E. E. Santala, Miia Artama, Eero Pukkala, Kala Visvanathan, Synnove Staff, Teemu J. Murtola

Summary: Research suggests that different antihypertensive drugs may be associated with the survival of ovarian cancer patients, with ACE inhibitors potentially improving survival rates. There appears to be no immediate impact of antihypertensive drugs on ovarian cancer survival, but over time, particularly with longer follow-up, certain medications may show benefits in improving survival outcomes. Further studies are needed to confirm the potential survival benefits of ACE inhibitors for women with ovarian cancer.

CANCERS (2021)

Add to Collection

Article Obstetrics & Gynecology

Substantial Lymphovascular Space Invasion Is an Adverse Prognostic Factor in High-Risk Endometrial Cancer

Elke E. M. Peters, Alicia Leon-Castillo, Estrid Hogdall, Marie Boennelycke, Vincent T. H. B. M. Smit, Claus Hogdall, Carien L. Creutzberg, Tjalling Bosse, Remi A. Nout, Gitte Ortoft

Summary: This study aimed to determine whether the extent of lymphovascular space invasion (LVSI) can serve as a prognostic factor in patients with high-risk endometrial cancer (HREC). The study found that substantial LVSI is an independent adverse prognostic factor for lymph node and distant metastases in HREC patients, leading to reduced survival. Therefore, the extent of LVSI should be incorporated into routine pathology reports to guide the appropriate choice of adjuvant treatment.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2022)

Add to Collection

Article Obstetrics & Gynecology

Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer

Elke E. M. Peters, Alicia Leon-Castillo, Vincent T. H. B. M. Smit, Marie Boennelycke, Estrid Hogdall, Claus Hogdall, Carien Creutzberg, Ina M. Jurgenliemk-Schulz, Jan J. Jobsen, Jan Willem M. Mens, Ludy C. H. W. Lutgens, Elzbieta M. Van der Steen-Banasik, Gitte Ortoft, Tjalling Bosse, Remi Nout

Summary: This study aimed to improve the accuracy of measuring clinically meaningful LVSI by quantitatively analyzing the correlation between LVSI and the risk of pelvic lymph node recurrence in EC. The study found that a numeric threshold (>= 4 LVSI-involved vessels in at least one H&E slide) can be used to define clinically relevant LVSI in EC.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2022)

Add to Collection

Article Obstetrics & Gynecology

Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer

Sarah Mejer Sorensen, Claus Hogdall, Berit Jul Mosgaard, Maya Isabella Riise Dalgaard, Mai Partridge Jensen, Katrine Fuglsang, Tine Henrichsen Schnack

Summary: The impact of primary debulking surgery (PDS) versus interval debulking surgery (IDS) on the overall survival (OS) of women with FIGO Stage IV epithelial ovarian cancer is debated. This study compared the outcomes of PDS and IDS in terms of the impact of intra-abdominal residual tumor, Stage IVA vs IVB, as well as the localization and number of metastases defining Stage IV disease. The results showed similar OS in patients with Stage IV disease treated with PDS and IDS. Complete intra-abdominal tumor resection improved the prognosis in both PDS and IDS. Malignant pleural effusion seemed to be a negative prognostic factor and should be further investigated in future studies.

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2022)

Add to Collection

Review Oncology

Prospects of Improving Early Ovarian Cancer Diagnosis Using Cervical Cell Swabs

Edyta Biskup, Regitze Solling Wils, Claus Hogdall, Estrid Hogdall

Summary: In this article, the potential use of cervical cell swabs (Pap specimens, liquid) for early detection of ovarian cancer (OC) is reviewed. The article presents the main findings of studies focusing on gene mutation detection and methylation profile analysis using Pap specimens, as well as one study proposing the use of peptide biomarkers in Pap-test fluid. The challenges and ideas for improved detection are also discussed.

ANTICANCER RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

Eileen O. Dareng, Jonathan P. Tyrer, Daniel R. Barnes, Michelle R. Jones, Xin Yang, Katja K. H. Aben, Muriel A. Adank, Simona Agata, Irene L. Andrulis, Hoda Anton-Culver, Natalia N. Antonenkova, Gerasimos Aravantinos, Banu K. Arun, Annelie Augustinsson, Judith Balmana, Elisa Bandera, Rosa B. Barkardottir, Daniel Barrowdale, Matthias W. Beckmann, Alicia Beeghly-Fadiel, Javier Benitez, Marina Bermisheva, Marcus Q. Bernardini, Line Bjorge, Amanda Black, Natalia Bogdanova, Bernardo Bonanni, Ake Borg, James D. Brenton, Agnieszka Budzilowska, Ralf Butzow, Saundra S. Buys, Hui Cai, Maria A. Caligo, Ian Campbell, Rikki Cannioto, Hayley Cassingham, Jenny Chang-Claude, Stephen J. Chanock, Kexin Chen, Yoke-Eng Chiew, Wendy K. Chung, Kathleen B. M. Claes, Sarah Colonna, Linda S. Cook, Fergus J. Couch, Mary B. Daly, Fanny Dao, Eleanor Davies, Miguel de la Hoya, Robin de Putter, Joe Dennis, Allison DePersia, Peter Devilee, Orland Diez, Yuan Chun Ding, Jennifer A. Doherty, Susan M. Domchek, Thilo Dork, Andreas du Bois, Matthias Durst, Diana M. Eccles, Heather A. Eliassen, Christoph Engel, Gareth D. Evans, Peter A. Fasching, James M. Flanagan, ReneeT Fortner, Eva Machackova, Eitan Friedman, Patricia A. Ganz, Judy Garber, Francesca Gensini, Graham G. Giles, Gord Glendon, Andrew K. Godwin, Marc T. Goodman, Mark H. Greene, Jacek Gronwald, Opal Study Group, AOCSGroup, Eric Hahnen, Christopher A. Haiman, Niclas Hakansson, Ute Hamann, Thomas V. O. Hansen, Holly R. Harris, Mikael Hartman, Florian Heitz, Michelle A. T. Hildebrandt, Estrid Hogdall, Claus K. Hogdall, John L. Hopper, Ruea-Yea Huang, Chad Huff, Peter J. Hulick, David G. Huntsman, Evgeny N. Imyanitov, Claudine Isaacs, Anna Jakubowska, Paul A. James, Ramunas Janavicius, Allan Jensen, Oskar Th Johannsson, Esther M. John, Michael E. Jones, Daehee Kang, Beth Y. Karlan, Anthony Karnezis, Linda E. Kelemen, Elza Khusnutdinova, Lambertus A. Kiemeney, Byoung-Gie Kim, Susanne K. Kjaer, Ian Komenaka, Jolanta Kupryjanczyk, Allison W. Kurian, Ava Kwong, Diether Lambrechts, Melissa C. Larson, Conxi Lazaro, Nhu D. Le, Goska Leslie, Jenny Lester, Fabienne Lesueur, Douglas A. Levine, Lian Li, Jingmei Li, Jennifer T. Loud, Karen H. Lu, Phuong L. Mai, Siranoush Manoukian, Jeffrey R. Marks, Rayna KimMatsuno, Keitaro Matsuo, Taymaa May, Lesley McGuffog, John R. McLaughlin, Iain A. McNeish, Noura Mebirouk, Usha Menon, Austin Miller, Roger L. Milne, Albina Minlikeeva, Francesmary Modugno, Marco Montagna, Kirsten B. Moysich, Elizabeth Munro, Katherine L. Nathanson, Susan L. Neuhausen, Heli Nevanlinna, Joanne Ngeow Yuen Yie, Henriette Roed Nielsen, Finn C. Nielsen, Liene Nikitina-Zake, Kunle Odunsi, Kenneth Offit, Edith Olah, Siel Olbrecht, Olufunmilayo Olopade, Sara H. Olson, Hakan Olsson, Ana Osorio, Laura Papi, Sue K. Park, Michael T. Parsons, Harsha Pathak, Inge Sokilde Pedersen, Ana Peixoto, Tanja Pejovic, Pedro Perez-Segura, Jennifer B. Permuth, Beth Peshkin, Paolo Peterlongo, Anna Piskorz, Darya Prokofyeva, Paolo Radice, Johanna Rantala, Marjorie J. Riggan, Harvey A. Risch, Cristina Rodriguez-Antona, Eric Ross, Mary Anne Rossing, Ingo Runnebaum, Dale P. Sandler, Marta Santamarina, Penny Soucy, Rita K. Schmutzler, V. Wendy Setiawan, Kang Shan, Weiva Sieh, Jacques Simard, Christian F. Singer, Anna P. Sokolenko, Honglin Song, Melissa C. Southey, Helen Steed, Dominique Stoppa-Lyonnet, Rebecca Sutphen, Anthony J. Swerdlow, Yen Yen Tan, Manuel R. Teixeira, Soo Hwang Teo, Kathryn L. Terry, Mary BethTerry, Mads Thomassen, Pamela J. Thompson, Liv Cecilie Vestrheim Thomsen, Darcy L. Thull, Marc Tischkowitz, Linda Titus, Amanda E. Toland, Diana Torres, Britton Trabert, Ruth Travis, Nadine Tung, Shelley S. Tworoger, Ellen Valen, Anne M. van Altena, Annemieke H. van der Hout, ElsVan Nieuwenhuysen, Elizabeth J. van Rensburg, Ana Vega, Digna Velez Edwards, Robert A. Vierkant, Frances Wang, Barbara Wappenschmidt, Penelope M. Webb, Clarice R. Weinberg, Jeffrey N. Weitzel, Nicolas Wentzensen, Emily White, Alice S. Whittemore, Stacey J. Winham, Alicja Wolk, Yin-Ling Woo, Anna H. Wu, Li Yan, Drakoulis Yannoukakos, Katia M. Zavaglia, Wei Zheng, Argyrios Ziogas, Kristin K. Zorn, Zdenek Kleibl, Douglas Easton, Kate Lawrenson, Anna DeFazio, Thomas A. Sellers, Susan J. Ramus, Celeste L. Pearce, Alvaro N. Monteiro, Julie Cunningham, Ellen L. Goode, Joellen M. Schildkraut, Andrew Berchuck, Georgia Chenevix-Trench, Simon A. Gayther, Antonis C. Antoniou, Paul D. P. Pharoah

Summary: This study developed polygenic risk score models for risk prediction of epithelial non-mucinous ovarian cancer and validated their predictive value in diverse populations and BRCA1/BRCA2 mutation carriers, suggesting potential clinical utility in ovarian cancer prevention programs.

EUROPEAN JOURNAL OF HUMAN GENETICS (2022)

Add to Collection

Article Oncology

Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study

Anne Weng Ekmann-Gade, Claus Kim Hogdall, Lene Seibaek, Mette Calundann Noer, Carsten Lindberg Fago-Olsen, Tine Henrichsen Schnack

Summary: The study examined clinical trends in younger and older epithelial ovarian cancer patients in Denmark, revealing a decrease in incidence, improvement in treatment options and cancer-specific survival rates, particularly in younger patients. However, older patients still experience lower survival rates. The proportion of advanced EOC patients not undergoing debulking surgery has increased significantly, while the percentage of patients debulked to no residual disease has also increased.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment

Alicia Leon-Castillo, Nanda Horeweg, Elke E. M. Peters, Tessa Rutten, Natalja ter Haar, Vincent T. H. B. M. Smit, Cor D. Kroon, Marie Boennelycke, Estrid Hogdall, Claus Hogdall, Remi R. A. Nout, Carien L. Creutzberg, Gitte Ortoft, Tjalling Bosse

Summary: The study evaluates the clinical outcome of molecular subgroups in high-grade endometrial cancer (EC) patients staged with lymphadenectomy and those without adjuvant treatment. The molecular classification has strong prognostic value, independent of clinicopathological factors. The unfavorable prognosis of early-stage p53abn EC is not due to undetected lymph node metastasis, and the indolent behavior of POLEmut EC is independent of adjuvant treatment.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Assessment of recurrence rate and risk factors of relapse in stage in IA vulvar carcinoma

Julie L. Schleiss-Andreassen, Elisabeth Kristensen, Ligita Paskeviciute Froding, Estrid Staehr, Claus Hogdall, Anne Pernille Christiansen, Estrid Hogdall, Tine Henrichsen Schnack

Summary: This study evaluated recurrence rates and risk factors of relapse in stage IA vulvar squamous cell carcinoma patients, finding that resection margins <8 mm and tumor size were associated with cancer recurrence. The study suggested that pathological assessment of stage IA VSCC may be difficult and further clarification of measurement methods is needed.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Pathology

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

Eun Young Kang, Joshua Millstein, Gordana Popovic, Nicola S. Meagher, Adelyn Bolithon, Aline Talhouk, Derek S. Chiu, Michael S. Anglesio, Betty Leung, Katrina Tang, Neil Lambie, Marina Pavanello, Annalyn Da-Anoy, Diether Lambrechts, Liselore Loverix, Siel Olbrecht, Christiani Bisinotto, Jesus Garcia-Donas, Sergio Ruiz-Llorente, Monica Yague-Fernandez, Robert P. Edwards, Esther Elishaev, Alexander Olawaiye, Sarah Taylor, Beyhan Ataseven, Andreas du Bois, Philipp Harter, Jenny Lester, Claus K. Hogdall, Sebastian M. Armasu, Yajue Huang, Robert A. Vierkant, Chen Wang, Stacey J. Winham, Sabine Heublein, Felix K. F. Kommoss, Daniel W. Cramer, Naoko Sasamoto, Lilian Van-Wagensveld, Maria Lycke, Constantina Mateoiu, Janine Joseph, Malcolm C. Pike, Kunle Odunsi, Chiu-Chen Tseng, Celeste L. Pearce, Sanela Bilic, Thomas P. Conrads, Arndt Hartmann, Alexander Hein, Michael E. Jones, Yee Leung, Matthias W. Beckmann, Matthias Ruebner, Minouk J. Schoemaker, Kathryn L. Terry, Mona A. El-Bahrawy, Penny Coulson, John L. Etter, Katherine LaVigne-Mager, Juergen Andress, Marcel Grube, Anna Fischer, Nina Neudeck, Greg Robertson, Rhonda Farrell, Ellen Barlow, Carmel Quinn, Anusha Hettiaratchi, Yovanni Casablanca, Ramona Erber, Colin J. R. Stewart, Adeline Tan, Yu Yu, Jessica Boros, Alison H. Brand, Paul R. Harnett, Catherine J. Kennedy, Nikilyn Nevins, Terry Morgan, Peter A. Fasching, Ignace Vergote, Anthony J. Swerdlow, Francisco J. Candido Dos Reis, G. Larry Maxwell, Susan L. Neuhausen, Arantzazu Barquin-Garcia, Francesmary Modugno, Kirsten B. Moysich, Philip J. Crowe, Akira Hirasawa, Florian Heitz, Beth Y. Karlan, Ellen L. Goode, Peter Sinn, Hugo M. Horlings, Estrid Hogdall, Karin Sundfeldt, Stefan Kommoss, Annette Staebler, Anna H. Wu, Paul A. Cohen, Anna DeFazio, Cheng-Han Lee, Helen Steed, Nhu D. Le, Simon A. Gayther, Kate Lawrenson, Paul D. P. Pharoah, Gottfried Konecny, Linda S. Cook, Susan J. Ramus, Linda E. Kelemen, Martin Kobel

Summary: MCM3 mRNA and protein expression levels are associated with survival in patients with tubo-ovarian high-grade serous carcinomas (HGSC), showing a correlation between high MCM3 expression and longer overall survival.

VIRCHOWS ARCHIV (2022)

Add to Collection

Article Immunology

Are we ready for translational research based on material and data from the Danish CancerBiobank and can we gain new knowledge from biobank registration?

Estrid V. S. Hogdall, Ib Jarle Christensen, Claus Hogdall

Summary: Bio-and GenomeBank, Denmark (RBGB) is a national infrastructure that includes the Danish CancerBiobank (DCB). This study aimed to assess the collected biological material in DCB for patients with primary ovarian cancer registered in The Danish Gynecologic Cancer Database (DGCD) and investigate the concordance between predicted organ of disease and final diagnosis. Data from DGCD and DCB were extracted. 62% of the patients with primary ovarian cancer (1347 out of 2172) had biological materials stored in DCB. The median age of patients with biological material in DCB was 67 years, while it was 69 years for patients without biological material (p = 0.0001).

APMIS (2023)

Add to Collection

Article Hematology

Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas

Marie Fredslund Breinholt, Lone Schejbel, Anne Ortved Gang, Torsten Holm Nielsen, Lars Moller Pedersen, Estrid Hogdall, Peter Norgaard

Summary: In this study, next generation sequencing (NGS) analysis was implemented in routine diagnostic work-up for B-cell non-Hodgkin's lymphoma (B-NHL). Mutations were detected in 94% of samples, and 50% of unclassified cases could be assigned a likely diagnostic subtype based on mutational findings. This gene sequencing approach provides potential diagnostic, prognostic, and predictive value for classification and risk-stratification of B-NHL.

EUROPEAN JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Oncology

Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer

Simon Ezban Grutzmeier, Bojan Kovacevic, Peter Vilmann, Charlotte Vestrup Rift, Linea Cecilie Melchior, Morten Orebo Holmstrom, Lene Brink, Hazem Hassan, John Gasdal Karstensen, Hanne Grossjohann, Deepthi Chiranth, Anders Toxvaerd, Carsten Palnaes Hansen, Estrid Hogdall, Jane Preuss Hasselby, Pia Klausen

Summary: Pancreatic cancer is a devastating disease with a low survival rate. Patient-derived 3D cultures have shown promise for personalized treatment, but most models do not include supportive tissue cells. In this study, a co-culture model was created using cells from endoscopic biopsies, showing interaction between tumor and stromal cells. The study also highlights the need to include cancer-associated fibroblasts (CAFs) in models, as CAFs impact treatment response.

CANCERS (2023)

Add to Collection

Article Immunology

Are we ready for translational research based on material and data from the Danish CancerBiobank and can we gain new knowledge from biobank registration?

Estrid V. S. Hogdall, Ib Jarle Christensen, Claus Hogdall

Summary: Bio-and GenomeBank, Denmark (RBGB) is a nationwide infra-structure. Danish Cancer Biobank (DCB) is a biobank in RBGB. The aim of this study is to evaluate the degree of biological material collected in DCB for primary ovarian cancer patients and investigate the concordance between presumed diagnosis and final diagnosis. Data extraction from relevant databases showed that biological materials were present for 62% of primary ovarian cancer patients. The optimal possibility for translational research and the potential need for additional biomarkers to aid in patient treatment were also highlighted.

APMIS (2023)

Add to Collection

Article Medicine, General & Internal

Rescue of Low-Yield DNA Samples for Next-Generation Sequencing Using Vacuum Centrifugal Concentration in a Clinical Workflow

Lau K. Vestergaard, Nicolai S. Mikkelsen, Douglas V. N. P. Oliveira, Tim S. Poulsen, Estrid V. Hoegdall

Summary: The implementation of next-generation sequencing (NGS) in clinical oncology allows for the analysis of multiple cancer-associated genes. Detection of pathogenic mutations is crucial for disease management. Obtaining the mutational profile is challenging in samples with low DNA yields, such as FFPE tissue and needle biopsies. This study demonstrates that vacuum centrifugation can concentrate low-yield DNA samples without compromising the mutational profile.

REPORTS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Identification of stably expressed microRNAs in plasma from high-grade serous ovarian carcinoma and benign tumor patients

Patrick H. D. Petersen, Joanna Lopacinska-Jorgensen, Claus K. Hogdall, Estrid V. Hogdall

Summary: This study aimed to identify microRNAs that are stably expressed in the plasma of HGSOC and benign ovarian tumor patients. RNA was isolated from plasma samples of 60 HGSOC and 48 benign patients, and RT-qPCR was performed to analyze the stability of 40 microRNAs and 8 controls. It was found that hsa-miR-126-3p and hsa-miR-23a-3p were the most stable miRNAs in HGSOC samples, while hsa-miR-191-5p and hsa-miR-27a-3p were the most stable in benign samples.

MOLECULAR BIOLOGY REPORTS (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.